| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1015836720294 |
| P698 | PubMed publication ID | 1798669 |
| P2093 | author name string | J. A. Moore | |
| B. L. Ferraiolo | |||
| S. A. Chen | |||
| J. D. Green | |||
| J. Mordenti | |||
| P2860 | cites work | The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man | Q28296423 |
| A specific growth hormone-binding protein in human plasma: initial characterization | Q28307442 | ||
| The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain | Q29618472 | ||
| Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial | Q34258431 | ||
| Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin | Q36587604 | ||
| Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. | Q36831159 | ||
| Identification and characterization of specific binding proteins for growth hormone in normal human sera | Q36994213 | ||
| Carbohydrate structures of recombinant soluble human CD4 expressed in Chinese hamster ovary cells | Q38336183 | ||
| Structural characterization of a recombinant CD4-IgG hybrid molecule | Q38337797 | ||
| Characterization of a soluble form of human CD4. Peptide analyses confirm the expected amino acid sequence, identify glycosylation sites and demonstrate the presence of three disulfide bonds | Q38341588 | ||
| Cellular catabolism of recombinant tissue-type plasminogen activator. Identification and characterization of a novel high affinity uptake system on rat hepatocytes | Q38889325 | ||
| The CD4 antigen: physiological ligand and HIV receptor | Q39184539 | ||
| Plasminogen activator inhibitors | Q39592746 | ||
| Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm | Q40200348 | ||
| The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone | Q41480434 | ||
| The pharmacokinetics and pharmacodynamics of a human relaxin in the mouse pubic symphysis bioassay | Q41829686 | ||
| Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects | Q43760717 | ||
| Characterization studies of human tissue-type plasminogen activator produced by recombinant DNA technology | Q43849753 | ||
| Biological properties of a CD4 immunoadhesin | Q43890550 | ||
| Purification and characterization of a melanoma cell plasminogen activator | Q44032827 | ||
| Renal extraction, filtration, absorption, and catabolism of growth hormone | Q44755419 | ||
| Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 TPA, in mice | Q44755442 | ||
| Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion | Q44867966 | ||
| The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. | Q46028626 | ||
| Designing CD4 immunoadhesins for AIDS therapy | Q46215386 | ||
| Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine | Q46828920 | ||
| Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli | Q48400430 | ||
| Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. | Q51774934 | ||
| Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. | Q52722509 | ||
| The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. | Q53824140 | ||
| Accessories or coreceptors? | Q58991614 | ||
| Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver | Q68359525 | ||
| The rabbit as a model for studies of fibrinolysis | Q68802826 | ||
| Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen | Q68833722 | ||
| The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator | Q69847645 | ||
| Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator | Q69859494 | ||
| Uptake and degradation of tissue plasminogen activator in rat liver | Q70410223 | ||
| Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site | Q70410232 | ||
| [Determination of the antiactivator activity in human and animal blood plasma using tissue plasminogen activator] | Q70457444 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biotechnology | Q7108 |
| organic chemistry | Q11351 | ||
| pharmacology | Q128406 | ||
| molecular medicine | Q3523816 | ||
| pharmaceutical science | Q7180763 | ||
| P304 | page(s) | 1351-1359 | |
| P577 | publication date | 1991-11-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins | |
| P478 | volume | 8 |
| Q30493126 | A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. |
| Q35842695 | A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats |
| Q84897048 | A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics |
| Q36087076 | Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model |
| Q28543054 | Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design |
| Q46829244 | Allometric principles for interspecies extrapolation in toxicological risk assessment--empirical investigations |
| Q28751304 | Allometric scaling of xenobiotic clearance: uncertainty versus universality |
| Q36912731 | Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. |
| Q73807182 | Assessment of biotechnology products for therapeutic use |
| Q28208717 | B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases |
| Q38067822 | Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development |
| Q90493457 | Design and Conduct Considerations for First-in-Human Trials |
| Q36620231 | Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. |
| Q28297407 | Elimination mechanisms of therapeutic monoclonal antibodies |
| Q36968126 | Engineering challenges for instrumenting and controlling integrated organ-on-chip systems |
| Q44599637 | Evaluation of the role of the asialoglycoprotein receptor in the clearance of UK-279,276 (recombinant neutrophil inhibitory factor) |
| Q40489530 | Immunoadhesins |
| Q36859972 | Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs |
| Q38701017 | Interspecies allometric scaling: prediction of clearance in large animal species: part II: mathematical considerations |
| Q42680392 | Interspecies modeling and prediction of human exenatide pharmacokinetics |
| Q52305453 | Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. |
| Q34011214 | Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs |
| Q35223673 | Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons |
| Q37616947 | Interspecies scaling of therapeutic monoclonal antibodies: initial look |
| Q36827999 | Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans |
| Q37267978 | Lasting reduction of cocaine action in neostriatum--a hydrolase gene therapy approach |
| Q45969172 | Long-acting growth hormones produced by conjugation with polyethylene glycol. |
| Q48732028 | Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling |
| Q36910611 | Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies |
| Q81951721 | Monoclonal antibody pharmacokinetics and pharmacodynamics |
| Q41433501 | Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody |
| Q33955695 | Nonclinical safety evaluation of biotechnologically derived pharmaceuticals |
| Q41854680 | Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler |
| Q36076282 | Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood. |
| Q40030334 | Pharmacokinetic Time Course Scaling of a Subcutaneously Administered Pegylated Peptide Conjugate for a First-in-Human Investigation |
| Q34636589 | Pharmacokinetics and molecular detoxication |
| Q73933442 | Pharmacokinetics of a hematoregulatory peptide (SK&F107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy |
| Q38072598 | Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies |
| Q44699279 | Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor |
| Q84431039 | Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals |
| Q52643801 | Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2. |
| Q40664366 | Prediction of drug clearance in humans from laboratory animals based on body surface area |
| Q33605312 | Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations |
| Q39805145 | Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance |
| Q88662678 | Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC |
| Q30930928 | Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. |
| Q52920937 | Prospective allometric scaling: does the emperor have clothes? |
| Q35192878 | Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition |
| Q51612613 | Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. |
| Q47800820 | Renal tolerance of digoxin-specific Fab fragments in the rat. |
| Q45050521 | Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism |
| Q73480165 | Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial |
| Q93928553 | Role of sialylation in determining the pharmacokinetics of neutrophil inhibitory factor (NIF) in the Fischer 344 rat |
| Q40545249 | Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys |
| Q37055123 | Scaling pharmacodynamics from in vitro and preclinical animal studies to humans |
| Q38215304 | Serelaxin : a potential new drug for the treatment of acute heart failure |
| Q71616231 | Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism |
| Q38264736 | Strategic approaches to optimizing peptide ADME properties |
| Q90433468 | The Influence of the Different Disposition Characteristics of Snake Toxins on the Pharmacokinetics of Snake Venom |
| Q44767990 | The pharmacokinetics and absorption of recombinant human relaxin in nonpregnant rabbits and rhesus monkeys after intravenous and intravaginal administration |
| Q43709444 | The pharmacokinetics and metabolism of human relaxins in rhesus monkeys |
| Q43716246 | The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration |
| Q35572362 | The role of pharmacokinetics in the development of biotechnologically derived agents |
| Q92892125 | Thermoresponsive and Protease-Cleavable Interferon-Polypeptide Conjugates with Spatiotemporally Programmed Two-Step Release Kinetics for Tumor Therapy |
| Q57292792 | Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology |
| Q38455786 | Tools for predicting the PK/PD of therapeutic proteins |
| Q57093607 | Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose |
| Q39963734 | Translational mixed-effects PKPD modelling of recombinant human growth hormone - from hypophysectomized rat to patients. |
| Q96165855 | Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations |
Search more.